Fevipiprant from BOC Sciences

Supplier Page

Supplier Page from
BOC Sciences for
Fevipiprant

Description

Fevipipran is a reversible competitive CRTh2 antagonist with IC50 value of 0.44 nM for inhibition of PGD2-induced eosinophil shape change in human whole blood. Now it is in Phase III clinical trials for the treatment of asthma